PMID- 31514228
OWN - NLM
STAT- MEDLINE
DCOM- 20210507
LR  - 20211204
IS  - 1440-1681 (Electronic)
IS  - 0305-1870 (Linking)
VI  - 47
IP  - 2
DP  - 2020 Feb
TI  - KIF2 mediates the neuroprotection in cerebral ischaemia injury by affecting NF-kappaB 
      pathway.
PG  - 274-280
LID - 10.1111/1440-1681.13175 [doi]
AB  - Stroke is the most common cerebrovascular disease with high morbidity and 
      mortality around the world. However, the underlying mechanisms involved in nerve 
      injury and cerebral ischaemia/reperfusion (I/R) during cerebrovascular disease 
      are still not completely clear. In the present study, we investigate the role of 
      kinesin family member 2 (KIF2) in the neuroprotection after cerebral I/R injury. 
      KIF2 was aberrantly expressed in the cerebral tissues from middle cerebral artery 
      occlusion (MCAO) rat model in a time dependent manner. A similar changing pattern 
      was found in the cultured hypoxic neurons as well as SK-N-SH cells in vitro. 
      Compared to the control, KIF2 inhibition significantly increased the level of 
      malonic dialdehyde (MDA), and reduced the level of superoxide dismutase (SOD) as 
      well as glutathione peroxidase (GSH-px) activity in cerebral tissues of MCAO rat 
      model. The reactive oxygen species (ROS) level was also up-regulated after KIF2 
      siRNA knockdown in cultured hypoxic SK-N-SH cells. The apoptosis rates of hypoxic 
      neurons and SK-N-SH cells as well as activated-caspase-3 level were obviously 
      increased after KIF2 silencing. Furthermore, we found that the nuclear 
      factor-kappa B (NF-kappaB) pathway was involved in KIF2-mediated neuroprotection 
      after cerebral I/R injury, and induced apoptosis of hypoxic SK-N-SH cells by KIF2 
      silencing could be attenuated by the specific inhibitor BAY11-7082 of NF-kappaB. In 
      conclusion, we demonstrate that KIF2 could mediate the neuroprotection in 
      cerebral I/R injury by inhibiting activation of NF-kappaB pathway. This might provide 
      a novel therapeutic target for cerebral I/R injury.
CI  - (c) 2019 John Wiley & Sons Australia, Ltd.
FAU - Wang, Jin
AU  - Wang J
AUID- ORCID: 0000-0002-5900-2954
AD  - Department of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 
      Shaanxi, China.
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - Chen, Jun
AU  - Chen J
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - Liu, Xifang
AU  - Liu X
AD  - Nerve & Spine Ward, Rehabilitation Center for TCM Orthopedics, Xi'an Honghui 
      Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
FAU - Yang, Haixia
AU  - Yang H
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - Liu, Jing
AU  - Liu J
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - He, Ali
AU  - He A
AD  - Department of Acupuncture, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
FAU - Gao, Xiaohang
AU  - Gao X
AD  - Department of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 
      Shaanxi, China.
FAU - Xin, Yinhu
AU  - Xin Y
AD  - Department of Encephalopathy, Shaanxi Provincial Hospital of Traditional Chinese 
      Medicine, Xi'an, Shaanxi, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191007
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (3-(4-methylphenylsulfonyl)-2-propenenitrile)
RN  - 0 (KIF2A protein, human)
RN  - 0 (NF-kappa B)
RN  - 0 (Nitriles)
RN  - 0 (Sulfones)
RN  - EC 3.6.4.4 (Kinesins)
SB  - IM
MH  - Animals
MH  - Brain Ischemia/*metabolism/prevention & control
MH  - Cell Line, Tumor
MH  - Humans
MH  - Kinesins/*biosynthesis
MH  - Male
MH  - NF-kappa B/antagonists & inhibitors/*metabolism
MH  - Neuroprotection/drug effects/*physiology
MH  - Nitriles/pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Reperfusion Injury/*metabolism/prevention & control
MH  - Signal Transduction/drug effects/*physiology
MH  - Sulfones/pharmacology
OTO - NOTNLM
OT  - KIF2
OT  - NF-kappaB pathway
OT  - apoptosis
OT  - cerebral I/R injury
OT  - oxidative stress
EDAT- 2019/09/13 06:00
MHDA- 2021/05/08 06:00
CRDT- 2019/09/13 06:00
PHST- 2018/08/30 00:00 [received]
PHST- 2019/09/05 00:00 [revised]
PHST- 2019/09/06 00:00 [accepted]
PHST- 2019/09/13 06:00 [pubmed]
PHST- 2021/05/08 06:00 [medline]
PHST- 2019/09/13 06:00 [entrez]
AID - 10.1111/1440-1681.13175 [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2020 Feb;47(2):274-280. doi: 10.1111/1440-1681.13175. 
      Epub 2019 Oct 7.